Company
Resilient Biotics
Breakthrough microbiome therapies for respiratory diseases
- Status
- Operatingas of 2026-09-19Source (opens in a new tab)
- Business model
- B2B
- Legal name
- Resilient Biotics
Claim, correct or request removal
Record updated 28 September 2026
About
Resilient is actively testing non-antibiotic, precision microbial therapeutics to prevent respiratory infectious diseases.
Funding snapshot
- Total raised
- $11MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $3.9M2022-08-16
Funding rounds
- Round, 2022
- $3.9M2022-08-16, SEC form D sold, 6 investors
- Round, 2020
- $7.2M2020-12-02, SEC form D sold, 18 investors
Loading relationship preview